GSK
NEWS
Heading into the holidays, there was still plenty of clinical trial news last week. Here’s a look.
Another recall has been issued for ranitidine tablets due to the presence of a carcinogen contaminant.
GlaxoSmithKline announced results from its pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s hires.
Submission follows completion of a Clinical Endpoint study
While there is no cure for the disease, there are a number of drugs that have been approved to treat the illness. And with the growing number of cases, the drug market for COPD is expected to dramatically increase as well.
Hertfordshire Local Enterprise Partnership is to invest £1.2m into Stevenage Bioscience Catalyst (SBC) to help grow a world-class cell and gene therapy cluster.
Inflammatory bowel disease (IBD) is an umbrella term for two conditions, Crohn’s disease and ulcerative colitis, that are characterized by chronic inflammation of the gastrointestinal (GI) tract. This chronic and prolonged inflammation results in damage to the GI tract.
It was a busy week for clinical trial announcements. Here’s a look.
JOBS
IN THE PRESS